Assessing baseline medication use in chronic kidney disease: An analysis of the SHARP-ER study

Similar Items

• Cause of death varies across Australia, New Zealand and Malaysia in those on renal replacement therapy - Results from the Study of Heart And Renal Protection-Extended Review (SHARP-ER)
  by: Talbot, B, et al.
  Published: (2018)
• Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort
  by: Louisa Sukkar, et al.
  Published: (2019-10-01)
• Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
  by: Baigent, C, et al.
  Published: (2010)
• Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial
  by: Ninomiya, T, et al.
  Published: (2008)
• Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
  by: Herrington, WG, et al.
  Published: (2023)